Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
06 08 2019
Historique:
entrez: 6 8 2019
pubmed: 6 8 2019
medline: 5 1 2021
Statut: ppublish

Résumé

Background Adenosine is a ubiquitous regulatory molecule known to modulate signaling in many cells and processes vital to vascular homeostasis. While studies of adenosine receptors have dominated research in the field, quantification of adenosine systemically and locally remains limited owing largely to technical restrictions. Given the potential clinical implications of adenosine biology, there is a need for adequately powered studies examining the role of plasma adenosine in vascular health. We sought to describe the analytical and biological factors that affect quantification of adenosine in humans in a large, real-world cohort of patients undergoing evaluation for coronary artery disease. Methods and Results Between November 2016 and April 2018, we assessed 1141 patients undergoing angiography for evaluation of coronary artery disease. High-performance liquid chromatography was used for quantification of plasma adenosine concentration, yielding an analytical coefficient of variance (CV

Identifiants

pubmed: 31379241
doi: 10.1161/JAHA.119.012228
pmc: PMC6761640
doi:

Substances chimiques

Biomarkers 0
Adenosine K72T3FS567

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012228

Références

Crit Rev Clin Lab Sci. 1989;27(5):409-37
pubmed: 2679660
J Am Coll Cardiol. 2014 Mar 11;63(9):872-7
pubmed: 24291273
Diab Vasc Dis Res. 2019 Sep;16(5):478-482
pubmed: 31064214
Nature. 2009 Sep 10;461(7261):282-6
pubmed: 19741708
Circ Cardiovasc Interv. 2012 Dec;5(6):805-12
pubmed: 23149331
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
Scand J Clin Lab Invest. 1999 Nov;59(7):491-500
pubmed: 10667686
J Am Coll Cardiol. 2009 Sep 22;54(13):1123-30
pubmed: 19761931
Cancer Causes Control. 2010 Jun;21(6):847-51
pubmed: 20135215
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):792-6
pubmed: 18184815
Nat Rev Endocrinol. 2015 Apr;11(4):228-41
pubmed: 25687993
Lancet. 2018 Jan 27;391(10118):319-328
pubmed: 29146124
JACC Heart Fail. 2016 Sep;4(9):746-8
pubmed: 27522629
N Engl J Med. 2004 Dec 16;351(25):2599-610
pubmed: 15602020
Clin Chem Lab Med. 2006;44(4):366-78
pubmed: 16599827
Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):1046-52
pubmed: 19407243
Int J Cardiol. 2005 May 25;101(2):191-5
pubmed: 15882662
J Am Heart Assoc. 2016 Dec 16;5(12):
pubmed: 27986756
Clin Chem Lab Med. 2014 Sep;52(9):1341-6
pubmed: 24781675
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Clin Chem. 1997 Jan;43(1):52-8
pubmed: 8990222
Circulation. 2002 Jul 30;106(5):569-74
pubmed: 12147538
PLoS One. 2013 Apr 08;8(4):e60759
pubmed: 23579782
Eur J Heart Fail. 2017 Mar;19(3):357-365
pubmed: 27766733
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586
pubmed: 29805112
J Am Heart Assoc. 2019 Aug 6;8(15):e012228
pubmed: 31379241
Circulation. 1999 Mar 23;99(11):1422-5
pubmed: 10086964
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1004-13
pubmed: 17332491
Can J Cardiol. 2014 Jan;30(1):35-45
pubmed: 24286961
Am J Physiol. 1982 Oct;243(4):H536-45
pubmed: 7124961
Virchows Arch. 2009 Mar;454(3):273-81
pubmed: 19165499
Circulation. 1999 Mar 23;99(11):1397-9
pubmed: 10086958
Arterioscler Thromb Vasc Biol. 2010 Jan;30(1):90-7
pubmed: 19834107
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):870-8
pubmed: 22423039
Cardiovasc Hematol Disord Drug Targets. 2011 Mar 1;11(1):30-9
pubmed: 21446903
N Engl J Med. 1994 Aug 18;331(7):417-24
pubmed: 7880233
Circulation. 1997 Mar 18;95(6):1363-5
pubmed: 9118500
Can J Cardiol. 2016 Nov;32(11):1263-1282
pubmed: 27712954
ScientificWorldJournal. 2013 Dec 25;2013:404320
pubmed: 24453844
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s39-42
pubmed: 18174451
J Med Chem. 1982 Mar;25(3):197-207
pubmed: 6279840
Nat Rev Drug Discov. 2013 Apr;12(4):265-86
pubmed: 23535933
BMJ. 2010 Jun 23;340:c2289
pubmed: 20573762
Circ Res. 2002 Mar 22;90(5):531-8
pubmed: 11909816
Clin Chim Acta. 1994 Oct 14;230(1):63-8
pubmed: 7850994
J Immunol. 2009 Nov 15;183(10):6767-77
pubmed: 19846878
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
N Engl J Med. 2008 Jan 17;358(3):231-40
pubmed: 18199862
J Clin Invest. 2006 Jul;116(7):1913-23
pubmed: 16823489
Circulation. 1997 Jul 1;96(1):37-43
pubmed: 9236414
Cardiovasc Hematol Disord Drug Targets. 2019;19(2):109-131
pubmed: 30318008
Cardiovasc Res. 2016 Nov 1;112(2):590-605
pubmed: 28513806
J Am Coll Cardiol. 2000 Oct;36(4):1248-52
pubmed: 11028479
Heart. 2007 Aug;93(8):899-900
pubmed: 17639105

Auteurs

Trevor Simard (T)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.
Department of Cellular and Molecular Medicine University of Ottawa Canada.

Richard Jung (R)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.
Department of Cellular and Molecular Medicine University of Ottawa Canada.

Alisha Labinaz (A)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Mohammad Ali Faraz (MA)

Faculty of Medicine University of Ottawa Canada.

F Daniel Ramirez (FD)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Pietro Di Santo (P)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Dylan Perry-Nguyen (D)

Faculty of Medicine University of Ottawa Canada.

Ian Pitcher (I)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Pouya Motazedian (P)

Faculty of Medicine University of Ottawa Canada.

Chantal Gaudet (C)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.
Department of Cellular and Molecular Medicine University of Ottawa Canada.

Rebecca Rochman (R)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Jeffrey Marbach (J)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Paul Boland (P)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Kiran Sarathy (K)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Saleh Alghofaili (S)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Juan J Russo (JJ)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Etienne Couture (E)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Steven Promislow (S)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.

Rob S Beanlands (RS)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.
Department of Cellular and Molecular Medicine University of Ottawa Canada.

Benjamin Hibbert (B)

CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Canada.
Department of Cellular and Molecular Medicine University of Ottawa Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH